Cancer

NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles

SHELTON, CONNECTICUT / ACCESS Newswire / December 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"),…

2 months ago

Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President

Carolyn Bonner Succeeds James ('Jim') Quinlan Who Has Resigned for Health Reasons After Taking Medical Leave in September 2025 PHILADELPHIA,…

2 months ago

AIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Investor Closing Bell Series

Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, December 4th at 4:00 PM ETOCALA,…

2 months ago

Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis

MELBOURNE, Australia, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company…

2 months ago

CytoDyn Announces Resolution of Class Action Lawsuit

VANCOUVER, Washington, Dec. 01, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company…

2 months ago

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th

MOUNTAIN VIEW, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (Nasdaq: RNXT) (“RenovoRx” or “the Company”), a life sciences company…

2 months ago

Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP

December 1, 2025 Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP Biodexa Pharmaceuticals…

2 months ago

Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions

BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology…

2 months ago

INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer’s Patients

Boca Raton, FL, Dec. 01, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing inflammation…

2 months ago

Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025

ROCKVILLE, Md. and SUZHOU, China, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage…

2 months ago